High expression of CD9 and Epidermal Growth Factor Receptor promotes the development of tongue cancer.

P C Suhasini, Vadisha Bhat, Shilpa S Shetty, Praveen Kumar Shetty, P G Roopashree, N Suchetha Kumari

Abstract read

In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.6field-weighted citation impact, top 34% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

CD9 knockdown inhibits cell proliferation, migration, and invasion and augments apoptosis in tongue cancer cells through regulation of the EGFR signalling pathway.Molecular biology reports · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

P C SuhasiniDepartment of Biochemistry, KS Hegde Medical Academy, NITTE (Deemed to be University), Mangalore, Karnataka, 575018, India.

Vadisha BhatDepartment of ENT, KS Hegde Medical Academy, NITTE (Deemed to be University), Mangalore, Karnataka, 575018, India.

Shilpa S ShettyCellomics, Lipdomics and Molecular Genetics division, Central Research Laboratory, KS Hegde Medical Academy, NITTE (Deemed to be University), Mangalore, Karnataka, 575018, India.

Praveen Kumar ShettyDepartment of Biochemistry, KS Hegde Medical Academy, NITTE (Deemed to be University), Mangalore, Karnataka, 575018, India.

P G RoopashreeDepartment of Biochemistry, KS Hegde Medical Academy, NITTE (Deemed to be University), Mangalore, Karnataka, 575018, India.

N Suchetha KumariDepartment of Biochemistry, KS Hegde Medical Academy, NITTE (Deemed to be University), Mangalore, Karnataka, 575018, India. kumarin@nitte.edu.in.

K S Hegde Medical Academy · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tongue cancer is distinguished by aggressive behavior, a high risk of recurrence, lymph, and distant metastases. Hypoxia-Induced Factor 1 α functions as a CD9 transcription factor. CD9 is a transmembrane protein that may be found on the cell membrane. It can modulate the expression of the Epidermal Growth Factor Receptor (EGFR) pathway. ELISA was used to measure serum CD9, p-EGFR, and p-Akt levels in 70 tongue cancer patients and 35 healthy controls. RT-PCR was used to analyze the gene expression of the related genes. The gene as well as protein expression of CD9, EGFR/p-EGFR, and Akt/p-Akt was significantly higher in case subjects when compared with the controls. The expression of CD9 was higher in case subjects who were smokers/alcoholics when to control subjects who were smokers/alcoholics. Overexpression of CD9 due to hypoxic conditions leads to the activation of EGFR-signaling pathway resulting in cancer progression, resistance to chemotherapy. Hence, CD9 could be a potential target to suppress cancer progression.

Indexed as

Proto-Oncogene Proteins c-aktTongue NeoplasmsCell Line, TumorEpidermal Growth FactorErbB ReceptorsHumansTetraspanin 29CD9 protein, humanEGFR protein, humanEpidermal Growth FactorErbB ReceptorsProto-Oncogene Proteins c-aktTetraspanin 29AktCD9EFGRHypoxiaTongue cancer

Identifiers

PMID38472425

DOI10.1007/s12032-024-02311-x

OpenAlexW4393320342

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.